Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs

PLoS Neglected Tropical Diseases

Volumn 5, Issue 5, 2011, Pages

  Aparicio Burgos, José E ^a   Ochoa García, Laucel ^a   Zepeda Escobar, José Antonio ^a   Gupta, Shivali ^b   Dhiman, Monisha ^b   Martínez, José Simón ^a   de Oca Jiménez, Roberto Montes ^a   Arreola, Margarita Val ^c   Barbabosa Pliego, Alberto ^a   Vázquez Chagoyán, Juan C ^a   Garg, Nisha Jain ^b  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Cardiology Clinic   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; MYELOPEROXIDASE; NITRITE; TRYPANOSOMA CRUZI VACCINE; PROTOZOAL VACCINE; PROTOZOON ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG; DRUG EFFICACY; DRUG SCREENING; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE INJURY; HEMAGGLUTINATION TEST; HISTOPATHOLOGY; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; NONHUMAN; PARASITEMIA; PHAGOCYTOSIS; PROTEIN BLOOD LEVEL; TRYPANOSOMA CRUZI; XENODIAGNOSIS; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; HEART MUSCLE; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; PATHOLOGY; PLASMID; TH1 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION TESTS; IMMUNIZATION, SECONDARY; MALE; MYOCARDIUM; PARASITEMIA; PLASMIDS; PROTOZOAN VACCINES; TH1 CELLS; VACCINATION; VACCINES, DNA;

EID: 79957987376     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001050     Document Type: Article

References (59)

1. World Health Organization (2010) Chagas disease control and elimination. Report of the secretariat. WHO, Geneva, UNDP/World Bank/WHO, http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_17-en.pdf.
2. Coura JR, Dias JC, (2009) Epidemiology, control, and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Oswaldo Cruz 104: 31-40.
3. Rassi A Jr, Rassi A, Marin-Neto JA, (2010) Chagas disease. Lancet 375: 1388-402.
4. Silveira EL, Claser C, Haolla FA, Zanella LG, Rodrigues MM, (2008) Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease. Clin Vaccine Immunol 15: 1292-300.
5. de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, et al. (2009) Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun 77: 4383-4395.
6. Bhatia V, Garg N, (2005) Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev Vaccines 4: 867-880.
7. Vázquez-Chagoyán JC, Gupta S, Garg NJ, (2011) Vaccine development against Trypanosoma cruzi and Chagas disease. Advanced Parasitol In press.
8. Garg N, Tarleton RL, (2002) Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 70: 5547-5555.
9. Bhatia V, Sinha M, Luxon B, Garg N, (2004) Utility of Trypanosoma cruzi sequence database for the identification of potential vaccine candidates: In silico and in vitro screening. Infect Immun 72: 6245-6254.
10. Bhatia V, Garg NJ, (2008) Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol 15: 1158-1164.
11. de Lana M, Chiari E, Tafuri WL, (1992) Experimental Chagas' disease in dogs. Mem Inst Oswaldo Cruz 87: 59-71.
12. Tafuri WL, de Lana M, Chiari E, Caliari MV, Bambirra EA, et al. (1988) Dogs as experimental models for the study of the natural course of Chagas disease. Rev Soc Bras Med Trop 21: e77.
13. Andrade ZA, Andrade SG, Sadigursky M, Wenthold RJ Jr, Hilbert SL, et al. (1997) The indeterminate phase of Chagas' disease: ultrastructural characterization of cardiac changes in the canine model. Am J Trop Med Hyg 57: 328-336.
14. Guedes PM, Veloso VM, Afonso LC, Caliari MV, Carneiro CM, et al. (2009) Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-gamma, TNF-alpha, and low IL-10 production during the acute infection phase. Vet Immunol Immunopathol 130: 43-52.
15. Barbabosa-Pliego A, Gil PC, Hernandez DO, Apparicio-Burgos E, de Oca-Kimenez RM, et al. (2010) Prevalence of Trypanosoma cruzi in dogs (Canis familiaris) and triatomines during 2008 in a sanitary region of the State of Mexico, Mexico. Vector Borne Zoonotic Dis 11 (2): 151-156.
16. Carneiro CM, Martins-Filho OA, Reis AB, Veloso VM, Araujo FM, et al. (2007) Differential impact of metacyclic and blood trypomastigotes on parasitological, serological and phenotypic features triggered during acute Trypanosoma cruzi infection in dogs. Acta Trop 101: 120-129.
17. Andrade ZA, (1991) Pathogenesis of Chagas disease. Res Immunol 142: 126-129.
18. Barbabosa-Pliego A, Díaz-Albiter HM, Ochoa-Garcia L, Aparicio-Burgos E, López-Heydeck S, et al. (2009) Trypanosoma cruzi circulating in the southern region of the State of Mexico (Zumpahuacan) is pathogenic: a dog model. Am J Trop Med Hyg 81: 390-395.
19. Goble FC, (1952) Observations on experimental Chagas' disease in dogs. Am J Trop Med Hyg 1: 189-204.
20. Lopes ER, Chapadeiro E, Andrade ZA, Almeida HO, Rocha A, (1981) Pathological anatomy of hearts from asymptomatic Chagas disease patients dying in a violent manner. Mem Inst Oswaldo Cruz 76: 189-97.
21. Cruz-Chan JV, Bolio-Gonzalez M, Colin-Flores R, Ramirez-Sierra MJ, Quijano-Hernandez I, et al. (2009) Immunopathology of natural infection with Trypanosoma cruzi in dogs. Vet Parasitol 162: 151-155.
22. Laranja FS, Dias E, Duarte E, Pellegrino J, (1951) Clinical and epidemiological observations on Chagas' disease in western Minas Gerais. Hospital (Rio J) 40: 945-988.
23. Laranja FS, Andrade ZA, (1980) Chronic cardiac form of Chagas disease in dogs. Arq Bras Cardiol 35: 377-380.
24. Gurtler RE, Kravetz FO, Petersen RM, Lauricella MA, Wisnivesky-Colli C, (1990) The prevalence of Trypanosoma cruzi and the demography of dog populations after insecticidal spraying of houses: a predictive model. Ann Trop Med Parasitol 84: 313-323.
25. Gurtler RE, Cecere MC, Castanera MB, Canale D, Lauricella MA, et al. (1996) Probability of infection with Trypanosoma cruzi of the vector Triatoma infestans fed on infected humans and dogs in northwest Argentina. Am J Trop Med Hyg 55: 24-31.
26. Gurtler RE, Cecere MC, Lauricella MA, Cardinal MV, Kitron U, et al. (2007) Domestic dogs and cats as sources of Trypanosoma cruzi infection in rural northwestern Argentina. Parasitology 134: 69-82.
27. Meurs KM, Anthony MA, Slater M, Miller MW, (1998) Chronic Trypanosoma cruzi infection in dogs: 11 cases (1987-1996). J Am Vet Med Assoc 213: 497-500.
28. Barr SC, Van Beek O, Carlisle-Nowak MS, Lopez JW, Kirchhoff LV, et al. (1995) Trypanosoma cruzi infection in Walker hounds from Virginia. Am J Vet Res 56: 1037-44.
29. Gurtler RE, Cohen JE, Cecere MC, Chuit R, (1997) Shifting host choices of the vector of Chagas disease Triatoma infecstans and the availability of hosts in houses in north-west Argentina. J Appl Ecol 34: 699-715.
30. NOM-033-ZOO NOM, (1995) Sacrificio Humanitario de los Animales Domésticos y Silvestre, http://www.cuautitlan.unam.mx/descargas/cicuae/normas/Norma033.pdf.
31. NOM-062-ZOO NOM, (1999) Especificaciones Técnicas para la Producción, Cuidado y Uso de los Animales del Laboratorio, http://www.fmvz.unam.mx/fmvz/principal/archivos/062ZOO.pdf.
32. Gupta S, Garg NJ, (2010) Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS Negl Trop Dis 4: e797.
33. Saldarriaga OA, Perez LE, Travi BL, Melby PC, (2006) Selective enhancement of the type 1 cytokine response by expression of a canine interleukin (IL)-12 fused heterodimeric DNA. Vet Immunol Immunopathol 110: 377-388.
34. Portela-Lindoso AA, Shikanai-Yasuda MA, (2003) Chronic Chagas' disease: from xenodiagnosis and hemoculture to polymerase chain reaction. Rev Saude Publica 37: 107-115.
35. Basso B, Castro I, Introini V, Gil P, Truyens C, Moretti E, (2007) Vaccination with Trypanosoma rangeli reduces the infectiousness of dogs experimentally infected with Trypanosoma cruzi. Vaccine 25: 3855-3858.
36. Bradley PP, Priebat DA, Christensen RD, Rothstein G, (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206-209.
37. Dhiman M, Estrada-Franco JG, Pando J, Ramirez-Aguilar F, Spratt H, et al. (2009) Increased myeloperoxidase activity and protein nitration are indicators of inflammation in chagasic patients. Clinical and Vaccine Immunology 16: 660-666.
38. Garg N, Popov VL, Papaconstantinou J, (2003) Profiling gene transcription reveals a deficiency of mitochondrial oxidative phosphorylation in Trypanosoma cruzi-infected murine hearts: implications in chagasic myocarditis development. Biochim Biophys Acta 1638: 106-120.
39. Garg N, Tarleton RL, (1998) Elicitation of protective cellular and humoral immune responses to Trypanosoma cruzi infection using DNA vaccines can be augmented with cytokines. Proceedings 10th International Congress of Immunology, New Delhi, India pp. 1421-1426.
40. Donnelly JJ, Wahren B, Liu MA, (2005) DNA vaccines: progress and challenges. J Immunol 175: 633-639.
41. Endmann A, Baden M, Weisermann E, Kapp K, Schroff M, et al. (2010) Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. Vaccine 28: 3642-3649.
42. Sakai T, Hisaeda H, Nakano Y, Ishikawa H, Maekawa Y, et al. (2000) Gene gun-mediated delivery of an interleukin-12 expression plasmid protects against infections with the intracellular protozoan parasites Leishmania major and Trypanosoma cruzi in mice. Immunology 99: 615-624.
43. Weinberg M, Waterman S, Lucas CA, Falcon VC, Morales PK, et al. (2003) The U.S.-Mexico border infectious disease surveillance project: establishing bi-national border surveillance. Emerg Infect Dis 9: 97-102.
44. Miyahira Y, Takashima Y, Kobayashi S, Matsumoto Y, Takeuchi T, et al. (2005) Immune responses against a single CD8+ T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 73: 7356-7365.
45. Cazorla SI, Becker PD, Frank FM, Ebensen T, Sartori MJ, et al. (2008) Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun 76: 324-333.
46. Moore AC, Hill AV, (2004) Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 199: 126-143.
47. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, et al. (2006) Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24: 4554-4561.
48. Guedes PM, Veloso VM, Gollob KJ, Afonso LC, Caldas IS, et al. (2008) IgG isotype profile is correlated with cardiomegaly in beagle dogs infected with distinct Trypanosoma cruzi strains. Vet Immunol Immunopathol 124: 163-168.
49. Coura-Vital W, Carneiro CM, Martins HR, de Lana M, Veloso VM, et al. (2008) Trypanosoma cruzi: immunoglobulin isotype profiles during the acute phase of canine experimental infection with metacyclic or blood trypomastigotes. Exp Parasitol 120: 269-274.
50. Cardoni RL, Antunez MI, Morales C, Nantes IR, (1997) Release of reactive oxygen species by phagocytic cells in response to live parasites in mice infected with Trypanosoma cruzi. Am J Trop Med Hyg 56: 329-334.
51. Piacenza L, Alvarez MN, Peluffo G, Radi R, (2009) Fighting the oxidative assault: the Trypanosoma cruzi journey to infection. Curr Opin Microbiol 12: 415-421.
52. Alvarez MN, Piacenza L, Irigoin F, Peluffo G, Radi R, (2004) Macrophage-derived peroxynitrite diffusion and toxicity to Trypanosoma cruzi. Arch Biochem Biophys 432: 222-232.
53. Zacks MA, Wen JJ, Vyatkina G, Bhatia V, Garg N, (2005) An overview of chagasic cardiomyopathy: pathogenic importance of oxidative stress. An Acad Bras Cienc 77: 695-715.
54. Junqueira C, Caetano B, Bartholomeu DC, Melo MB, Ropert C, et al. (2010) The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med 12: e29.
55. Cohen JE, Gurtler RE, (2001) Modeling household transmission of American trypanosomiasis. Science 293: 694-698.
56. Reithinger R, Ceballos L, Stariolo R, Davies CR, Gurtler RE, (2005) Chagas disease control: deltamethrin-treated collars reduce Triatoma infestans feeding success on dogs. Trans R Soc Trop Med Hyg 99: 502-508.
57. Reithinger R, Ceballos L, Stariolo R, Davies CR, Gurtler RE, (2006) Extinction of experimental Triatoma infestans populations following continuous exposure to dogs wearing deltamethrin-treated collars. Am J Trop Med Hyg 74: 766-771.
58. Guedes PM, Veloso VM, Caliari MV, Carneiro CM, Souza SM, et al. (2007) Trypanosoma cruzi high infectivity in vitro is related to cardiac lesions during long-term infection in beagle dogs. Mem Inst Oswaldo Cruz 102: 141-147.
59. Veloso VM, Guedes PM, Andrade IM, Caldas IS, Martins HR, et al. (2008) Trypanosoma cruzi: blood parasitism kinetics and their correlation with heart parasitism intensity during long-term infection of beagle dogs. Mem Inst Oswaldo Cruz 103: 528-34.